Developer docs
API playgroundTry for free, no card

Search company profiles

CrystalsFirst

Full company profile

uuid0003qjy

Namestring
CrystalsFirst
Legal namestring
CrystalsFirst GmbH
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CrystalsFirst GmbH is a Marburg, Germany-based contract research organization (CRO) founded in 2018 as a spin-out from Prof. Gerhard Klebe's structural biology group at Philipps University Marburg. The company provides structural biology and small-molecule drug discovery services to pharmaceutical and biotechnology clients, with a track record of structurally enabling 60+ drug targets and depositing 340+ structures in the Protein Data Bank. Its service offering spans protein production, de novo crystallization, co-crystallization, structural biology, computer-aided drug design (CADD), AI-driven drug design (AIDD), and hit identification.

The company's central technology is the MAGNET Discovery Engine, which integrates patented SmartSoak® high-throughput crystallographic fragment screening (10X faster soaking setup, 50%+ higher success rates vs. conventional methods) with FragAI, a proprietary 3D-aware generative AI platform trained on internal protein-ligand complex data and operating in a closed make-test-learn loop with experimental validation. CrystalsFirst is also the exclusive worldwide provider of NexMR's SmartSpin® photo-CIDNP NMR screening, capable of screening up to ~700-1,500 samples per day. The company positions itself on a "crystal structure first" paradigm — using crystallography as the primary fragment screening method rather than a downstream validation step — to access novel scaffolds, allosteric and cryptic pockets, and weak binders that conventional biophysical cascades miss.

Commercially, CrystalsFirst sells project-based, quote-driven service contracts to enterprise and mid-market pharma and biotech customers, acquired through enterprise field sales, conference presence (BIO, DDC, FBLD), webinars, and direct outreach. Named customers include Merck KGaA, AiCuris, KSQ Therapeutics, Flindr Therapeutics, and Think Bioscience. The company has a 40+ collaboration track record and operates from Marburg (headquarters) and Hamburg (R&D and operations at the DESY synchrotron, expanded in Q2 2025). Revenue is generated on a per-project, multi-year basis spanning target enablement, hit-to-lead, and lead optimization campaigns, with no public pricing disclosed.

Short descriptiontext

CrystalsFirst is a German CRO that delivers AI-augmented structural biology and small-molecule drug discovery services to pharmaceutical and biotechnology companies. Its MAGNET platform combines patented SmartSoak® crystallographic screening with proprietary FragAI generative AI for fragment-based hit identification and lead optimization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHamburg, Germany
HQ citystring
Hamburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fragment-based drug discovery, structural biology services, AI-driven molecular design, crystallographic fragment screening, drug discovery CRO
Industry2 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Services (CRO)
TypeProfessional Services
Description

CrystalsFirst operates as a Contract Research Organization (CRO) providing fee-for-service drug discovery and structural biology services to pharmaceutical and biotechnology companies. Services include crystallographic fragment screening (SmartSoak®), co-crystallization, de novo crystallization, SmartSpin® NMR screening, CADD, and AIDD. Revenue is generated on a project-by-project basis, with pricing quoted based on scope, complexity, and deliverables. Projects range from target enablement to hit-to-lead and lead optimization campaigns.

crystalsfirst.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based service contracts
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is determined on a per-project basis. The company offers a variety of stand-alone packages for crystallographic fragment screening and co-structure determination, as well as integrated drug research programs from early drug discovery to preclinical development. No public pricing is available; prospective clients submit inquiries through the website contact form.

crystalsfirst.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CrystalsFirst is a Contract Research Organization (CRO) that provides fee-for-service small-molecule drug discovery support to pharmaceutical and biotechnology companies. Its core offering is the MAGNET Discovery Engine, which integrates patented SmartSoak® high-throughput crystallographic fragment screening with proprietary FragAI 3D-aware generative AI, supported by co-crystallization, de novo crystallization, SmartSpin® ultrafast NMR screening, CADD, AIDD, protein production, and structural biology services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Over 60 drug targets structurally enabled for drug discovery across diverse protein families and modalities
+6 more records
Product overview1 text field

CrystalsFirst offers a unified platform approach centered on the MAGNET Discovery Engine, which integrates patented SmartSoak® crystallographic technology with proprietary FragAI generative AI for structure-first drug discovery. The platform encompasses modular services including SmartSoak® Screening and SmartSpin® Screening for hit identification, CADD and AIDD for computational design, and supporting services for Protein Production, Structural Biology, De Novo Crystallization, and Co-Crystallization. This integrated workflow enables seamless progression from target enablement through hit identification to lead optimization, with FastForward pipeline providing automated data processing throughout.

Product and service12 records
1MAGNET Discovery Engine
CategoryDrug Discovery Platform
Description

Core integrated platform combining patented high-throughput structural biology (SmartSoak®) with AI-powered molecular design (FragAI) for small-molecule drug discovery. Unites vertically scaling proprietary labware with horizontally scaling AI-driven design tools to systematically uncover, validate, and optimize ligands across target-to-hit, hit-to-lead, and lead optimization. Sold as integrated drug discovery programs to pharmaceutical and biotechnology clients.

2SmartSoak® Technology
CategoryStructural Biology Technology
Description

Patented first-of-its-kind soaking technology for protein crystals that accelerates the setup of soaking systems for X-ray crystallography. Delivers experimental soaking conditions up to 10X faster than industry standards with at least 50% higher success rates compared to conventional soaking. Offered as a core technology capability within CrystalsFirst's services.

3SmartSoak® Screening
CategoryFragment Screening Service
Description

Crystallographic fragment screening service using the SmartSoak® platform. Delivers unambiguous 3D binding events directly in protein structures, enabling discovery of novel scaffolds, allosteric binders, and conformational changes. Turnaround is as fast as two weeks from compound delivery to solved structure. For pharmaceutical and biotechnology drug discovery teams.

4SmartSpin® Screening
CategoryNMR Screening Service
Description

Ultra-fast NMR screening service exclusively offered by CrystalsFirst worldwide through NexMR partnership. Uses photo-hyperpolarization (photo-CIDNP) to detect fragment binding in seconds to minutes instead of hours, screening up to 700-1,500 samples per day. For pharmaceutical and biotechnology fragment-based drug discovery programs.

5FragAI Generative AI Platform
CategoryAI-Driven Drug Design
Description

Proprietary 3D-aware generative AI platform for fragment evolution, hit-to-lead, and lead optimization. Trained on experimental protein-ligand complexes produced in-house using reinforcement learning with multi-objective reward functions. Each campaign uses a unique generative model, providing full IP ownership to the client. Operates in closed make-test-learn loop with SmartSoak® experimental validation. For pharmaceutical and biotechnology drug discovery programs.

6Computer-Aided Drug Design (CADD)
CategoryComputational Drug Design Service
Description

Structure-guided CADD services including molecular docking, scoring functions (DSX), binding free energy calculations, and GPU/CPU-powered large-scale virtual screening. Workflows are integrated with structural biology data. Grounded in expertise from Prof. Gerhard Klebe's group. For pharmaceutical and biotechnology drug discovery teams.

7AI-Driven Drug Design (AIDD)
CategoryAI-Driven Drug Design Service
Description

Generative AI-powered molecular design service using the FragAI platform. Operates in closed loop with experimental validation for hit discovery and fragment-to-lead optimization. For pharmaceutical and biotechnology drug discovery programs.

8Protein Production
CategoryProtein Production Service
Description

Recombinant protein production services for crystallography-grade protein material. Includes expression optimization, purification, and quality control for drug discovery applications. For pharmaceutical and biotechnology structural biology and drug discovery programs.

9Structural Biology
CategoryStructural Biology Service
Description

High-resolution structural biology services including X-ray crystallography and integration with Cryo-EM. Provides atomic-level data for structure-based drug discovery. For pharmaceutical and biotechnology clients.

10De Novo Crystallization
CategoryCrystallization Service
Description

First-time crystallization services for proteins with no prior structural data. Uses broad screening kits, automation, robotic platforms, and systematic exploration of conditions including additive screens and seeding strategies. For drug discovery teams requiring novel protein structures.

11Co-Crystallization
CategoryCo-Crystallization Service
Description

High-throughput co-crystallization services embedding ligands or other proteins directly during crystal growth or earlier in protein purification. Supports non-covalent, covalent inhibitors, PROTACs, and protein-protein complexes. For pharmaceutical and biotechnology drug discovery programs.

12Hit Identification
CategoryHit Identification Service
Description

Integrated hit identification services combining SmartSoak® crystallographic screening, SmartSpin® NMR screening, CADD, and AIDD for comprehensive fragment and lead discovery. For pharmaceutical and biotechnology drug discovery programs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-04
Description

CrystalsFirst entered an exclusive worldwide partnership with NexMR AG to exclusively offer NexMR's SmartSpin™ ultrafast NMR screening technology for fragment-based drug discovery. The partnership combines NexMR's photo-inducible hyperpolarization NMR technology (SmartSpin™) with CrystalsFirst's MAGNET platform and SmartSoak® crystallography. SmartSpin™ uses laser systems to boost NMR signals, reducing screening time from over 200 hours to a few hours while decreasing sample amounts by 30–50X. This exclusive arrangement makes CrystalsFirst the sole provider of NexMR's photo-inducible NMR services worldwide. The partnership builds on a previous collaboration announced in July 2023 and was expanded to exclusive status in September 2025.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Evotec is a global discovery CRO with deep structural biology and FBDD capabilities operating integrated drug discovery platforms. Its target-to-lead and SBDD service portfolio directly competes with CrystalsFirst's MAGNET-enabled offerings for the same biotech and pharma buyers.

TypeDirect peer
Description

Schrödinger combines physics-based computational chemistry software with drug discovery services using live-design workflows. Its CADD/AI-driven SBDD offering closely parallels CrystalsFirst's CADD, AIDD and FragAI services for the same enterprise pharma buyers.

TypeDirect peer
Description

Vernalis operates an established FBDD and structure-based drug design CRO with proprietary fragment libraries and crystallography expertise. It targets the same biotech and pharma customers for crystallographic fragment screening as CrystalsFirst's SmartSoak® service.

TypeBroad incumbent
Description

Charles River is a large, established CRO offering discovery and safety assessment services including structural biology. Its discovery arm is part of a much broader portfolio and represents an entrenched incumbent competing for the same crystallography and FBDD program budgets.

TypeDirect peer
Description

XChem is a fragment-screening specialist CRO (Oxford Protein Production Facility spin-out) offering DEL and crystallographic fragment screening. Its service directly competes with CrystalsFirst's SmartSoak®/SmartSpin® hit-identification offerings.

6Isomorphic Labs
TypeEmerging player
Description

Isomorphic Labs (DeepMind spin-out) applies AlphaFold-derived AI to drug discovery with internal pharma partnerships. Although it is not a CRO, it competes for the same AI-driven SBDD/TPD outsourcing budgets from large pharma that would otherwise flow to CrystalsFirst-style CROs.

TypeEmerging player
Description

Recursion operates an AI-driven, high-throughput phenotypic and target-based drug discovery platform. Its model increasingly overlaps with CrystalsFirst's AI + structural biology thesis and competes for outsourced pharma discovery dollars.

TypeEmerging player
Description

PostEra is an AI-first preclinical drug discovery company combining generative chemistry with medicinal chemistry campaigns. It serves similar early-stage discovery clients and competes for AI + SBDD outsourcing budgets.

TypeEmerging player
Description

Insitro combines ML with disease modeling and target discovery. While its wet-lab focus is more cell biology-centric, it competes for the same 'AI-driven discovery' strategic budgets at pharma partners that may otherwise fund CrystalsFirst's platform engagements.

TypeOthers
Description

BioSolveIT develops scientific software for structure-based drug design (SeeSAR, infiniSee) used by SBDD researchers. It is both a collaborator (co-hosted webinars with CrystalsFirst) and a partial alternative for clients evaluating docking/virtual screening tools.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CrystalsFirst

Drug Discovery CRO Servicescrystalsfirst.com

CrystalsFirst is a German CRO that delivers AI-augmented structural biology and small-molecule drug discovery services to pharmaceutical and biotechnology companies. Its MAGNET platform combines patented SmartSoak® crystallographic screening with proprietary FragAI generative AI for fragment-based hit identification and lead optimization.

What CrystalsFirst does

CrystalsFirst GmbH is a Marburg, Germany-based contract research organization (CRO) founded in 2018 as a spin-out from Prof. Gerhard Klebe's structural biology group at Philipps University Marburg. The company provides structural biology and small-molecule drug discovery services to pharmaceutical and biotechnology clients, with a track record of structurally enabling 60+ drug targets and depositing 340+ structures in the Protein Data Bank. Its service offering spans protein production, de novo crystallization, co-crystallization, structural biology, computer-aided drug design (CADD), AI-driven drug design (AIDD), and hit identification.

The company's central technology is the MAGNET Discovery Engine, which integrates patented SmartSoak® high-throughput crystallographic fragment screening (10X faster soaking setup, 50%+ higher success rates vs. conventional methods) with FragAI, a proprietary 3D-aware generative AI platform trained on internal protein-ligand complex data and operating in a closed make-test-learn loop with experimental validation. CrystalsFirst is also the exclusive worldwide provider of NexMR's SmartSpin® photo-CIDNP NMR screening, capable of screening up to ~700-1,500 samples per day. The company positions itself on a "crystal structure first" paradigm — using crystallography as the primary fragment screening method rather than a downstream validation step — to access novel scaffolds, allosteric and cryptic pockets, and weak binders that conventional biophysical cascades miss.

Commercially, CrystalsFirst sells project-based, quote-driven service contracts to enterprise and mid-market pharma and biotech customers, acquired through enterprise field sales, conference presence (BIO, DDC, FBLD), webinars, and direct outreach. Named customers include Merck KGaA, AiCuris, KSQ Therapeutics, Flindr Therapeutics, and Think Bioscience. The company has a 40+ collaboration track record and operates from Marburg (headquarters) and Hamburg (R&D and operations at the DESY synchrotron, expanded in Q2 2025). Revenue is generated on a per-project, multi-year basis spanning target enablement, hit-to-lead, and lead optimization campaigns, with no public pricing disclosed.

CrystalsFirst firmographics

Firmographics
Name
CrystalsFirst
Legal name
CrystalsFirst GmbH
Website
https://crystalsfirst.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
CrystalsFirst is a German CRO that delivers AI-augmented structural biology and small-molecule drug discovery services to pharmaceutical and biotechnology companies. Its MAGNET platform combines patented SmartSoak® crystallographic screening with proprietary FragAI generative AI for fragment-based hit identification and lead optimization.
Ownership category
akta.pro rank

CrystalsFirst industry classification

Industry
Product category
Drug Discovery CRO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Fragment-based drug discovery
  • Structural biology services
  • AI-driven molecular design
  • Crystallographic fragment screening
  • Drug discovery CRO

Where CrystalsFirst is headquartered

Location

Headquarters

HQ city
Hamburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

CrystalsFirst business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Discovery Services (CRO): CrystalsFirst operates as a Contract Research Organization (CRO) providing fee-for-service drug discovery and structural biology services to pharmaceutical and biotechnology companies. Services include crystallographic fragment screening (SmartSoak®), co-crystallization, de novo crystallization, SmartSpin® NMR screening, CADD, and AIDD. Revenue is generated on a project-by-project basis, with pricing quoted based on scope, complexity, and deliverables. Projects range from target enablement to hit-to-lead and lead optimization campaigns.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based service contracts

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

CrystalsFirst product offering

Product offering

Core offering

CrystalsFirst is a Contract Research Organization (CRO) that provides fee-for-service small-molecule drug discovery support to pharmaceutical and biotechnology companies. Its core offering is the MAGNET Discovery Engine, which integrates patented SmartSoak® high-throughput crystallographic fragment screening with proprietary FragAI 3D-aware generative AI, supported by co-crystallization, de novo crystallization, SmartSpin® ultrafast NMR screening, CADD, AIDD, protein production, and structural biology services.

Product overview

CrystalsFirst offers a unified platform approach centered on the MAGNET Discovery Engine, which integrates patented SmartSoak® crystallographic technology with proprietary FragAI generative AI for structure-first drug discovery. The platform encompasses modular services including SmartSoak® Screening and SmartSpin® Screening for hit identification, CADD and AIDD for computational design, and supporting services for Protein Production, Structural Biology, De Novo Crystallization, and Co-Crystallization. This integrated workflow enables seamless progression from target enablement through hit identification to lead optimization, with FastForward pipeline providing automated data processing throughout.

Differentiator

Problem solved

Functional benefit

Products and services

  • MAGNET Discovery Engine Core integrated platform combining patented high-throughput structural biology (SmartSoak®) with AI-powered molecular design (FragAI) for small-molecule drug discovery. Unites vertically scaling proprietary labware with horizontally scaling AI-driven design tools to systematically uncover, validate, and optimize ligands across target-to-hit, hit-to-lead, and lead optimization. Sold as integrated drug discovery programs to pharmaceutical and biotechnology clients.
  • SmartSoak® Technology Patented first-of-its-kind soaking technology for protein crystals that accelerates the setup of soaking systems for X-ray crystallography. Delivers experimental soaking conditions up to 10X faster than industry standards with at least 50% higher success rates compared to conventional soaking. Offered as a core technology capability within CrystalsFirst's services.
  • SmartSoak® Screening Crystallographic fragment screening service using the SmartSoak® platform. Delivers unambiguous 3D binding events directly in protein structures, enabling discovery of novel scaffolds, allosteric binders, and conformational changes. Turnaround is as fast as two weeks from compound delivery to solved structure. For pharmaceutical and biotechnology drug discovery teams.
  • SmartSpin® Screening Ultra-fast NMR screening service exclusively offered by CrystalsFirst worldwide through NexMR partnership. Uses photo-hyperpolarization (photo-CIDNP) to detect fragment binding in seconds to minutes instead of hours, screening up to 700-1,500 samples per day. For pharmaceutical and biotechnology fragment-based drug discovery programs.
  • FragAI Generative AI Platform Proprietary 3D-aware generative AI platform for fragment evolution, hit-to-lead, and lead optimization. Trained on experimental protein-ligand complexes produced in-house using reinforcement learning with multi-objective reward functions. Each campaign uses a unique generative model, providing full IP ownership to the client. Operates in closed make-test-learn loop with SmartSoak® experimental validation. For pharmaceutical and biotechnology drug discovery programs.
  • Computer-Aided Drug Design (CADD) Structure-guided CADD services including molecular docking, scoring functions (DSX), binding free energy calculations, and GPU/CPU-powered large-scale virtual screening. Workflows are integrated with structural biology data. Grounded in expertise from Prof. Gerhard Klebe's group. For pharmaceutical and biotechnology drug discovery teams.
  • AI-Driven Drug Design (AIDD) Generative AI-powered molecular design service using the FragAI platform. Operates in closed loop with experimental validation for hit discovery and fragment-to-lead optimization. For pharmaceutical and biotechnology drug discovery programs.
  • Protein Production Recombinant protein production services for crystallography-grade protein material. Includes expression optimization, purification, and quality control for drug discovery applications. For pharmaceutical and biotechnology structural biology and drug discovery programs.
  • Structural Biology High-resolution structural biology services including X-ray crystallography and integration with Cryo-EM. Provides atomic-level data for structure-based drug discovery. For pharmaceutical and biotechnology clients.
  • De Novo Crystallization First-time crystallization services for proteins with no prior structural data. Uses broad screening kits, automation, robotic platforms, and systematic exploration of conditions including additive screens and seeding strategies. For drug discovery teams requiring novel protein structures.
  • Co-Crystallization High-throughput co-crystallization services embedding ligands or other proteins directly during crystal growth or earlier in protein purification. Supports non-covalent, covalent inhibitors, PROTACs, and protein-protein complexes. For pharmaceutical and biotechnology drug discovery programs.
  • Hit Identification Integrated hit identification services combining SmartSoak® crystallographic screening, SmartSpin® NMR screening, CADD, and AIDD for comprehensive fragment and lead discovery. For pharmaceutical and biotechnology drug discovery programs.

Quantifiable outcome

  • Over 60 drug targets structurally enabled for drug discovery across diverse protein families and modalities
  • +6 more outcomes

Companies that use CrystalsFirst

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

CrystalsFirst technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

CrystalsFirst partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NexMR AGcoreTechnology or Integration · 4 September 2025CrystalsFirst entered an exclusive worldwide partnership with NexMR AG to exclusively offer NexMR's SmartSpin™ ultrafast NMR screening technology for fragment-based drug discovery. The partnership combines NexMR's photo-inducible hyperpolarization NMR technology (SmartSpin™) with CrystalsFirst's MAGNET platform and SmartSoak® crystallography. SmartSpin™ uses laser systems to boost NMR signals, reducing screening time from over 200 hours to a few hours while decreasing sample amounts by 30–50X. This exclusive arrangement makes CrystalsFirst the sole provider of NexMR's photo-inducible NMR services worldwide. The partnership builds on a previous collaboration announced in July 2023 and was expanded to exclusive status in September 2025.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

CrystalsFirst competitors and assessment

Company assessment

Direct peers

  • Evotec: Evotec is a global discovery CRO with deep structural biology and FBDD capabilities operating integrated drug discovery platforms. Its target-to-lead and SBDD service portfolio directly competes with CrystalsFirst's MAGNET-enabled offerings for the same biotech and pharma buyers.
  • Schrödinger: Schrödinger combines physics-based computational chemistry software with drug discovery services using live-design workflows. Its CADD/AI-driven SBDD offering closely parallels CrystalsFirst's CADD, AIDD and FragAI services for the same enterprise pharma buyers.
  • Vernalis (R&D Services): Vernalis operates an established FBDD and structure-based drug design CRO with proprietary fragment libraries and crystallography expertise. It targets the same biotech and pharma customers for crystallographic fragment screening as CrystalsFirst's SmartSoak® service.
  • XChem: XChem is a fragment-screening specialist CRO (Oxford Protein Production Facility spin-out) offering DEL and crystallographic fragment screening. Its service directly competes with CrystalsFirst's SmartSoak®/SmartSpin® hit-identification offerings.

Broad incumbents

  • Charles River Laboratories: Charles River is a large, established CRO offering discovery and safety assessment services including structural biology. Its discovery arm is part of a much broader portfolio and represents an entrenched incumbent competing for the same crystallography and FBDD program budgets.

Emerging players

  • Isomorphic Labs: Isomorphic Labs (DeepMind spin-out) applies AlphaFold-derived AI to drug discovery with internal pharma partnerships. Although it is not a CRO, it competes for the same AI-driven SBDD/TPD outsourcing budgets from large pharma that would otherwise flow to CrystalsFirst-style CROs.
  • Recursion Pharmaceuticals: Recursion operates an AI-driven, high-throughput phenotypic and target-based drug discovery platform. Its model increasingly overlaps with CrystalsFirst's AI + structural biology thesis and competes for outsourced pharma discovery dollars.
  • PostEra: PostEra is an AI-first preclinical drug discovery company combining generative chemistry with medicinal chemistry campaigns. It serves similar early-stage discovery clients and competes for AI + SBDD outsourcing budgets.
  • Insitro: Insitro combines ML with disease modeling and target discovery. While its wet-lab focus is more cell biology-centric, it competes for the same 'AI-driven discovery' strategic budgets at pharma partners that may otherwise fund CrystalsFirst's platform engagements.

Others

  • BioSolveIT: BioSolveIT develops scientific software for structure-based drug design (SeeSAR, infiniSee) used by SBDD researchers. It is both a collaborator (co-hosted webinars with CrystalsFirst) and a partial alternative for clients evaluating docking/virtual screening tools.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

CrystalsFirst social profiles

Digital presence

CrystalsFirst financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CrystalsFirst leadership team

Management profile

Number of profiles

Profiles8 records

CrystalsFirst funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CrystalsFirst M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CrystalsFirst

What does CrystalsFirst do?

CrystalsFirst is a Contract Research Organization (CRO) that provides fee-for-service small-molecule drug discovery support to pharmaceutical and biotechnology companies. Its core offering is the MAGNET Discovery Engine, which integrates patented SmartSoak® high-throughput crystallographic fragment screening with proprietary FragAI 3D-aware generative AI, supported by co-crystallization, de novo crystallization, SmartSpin® ultrafast NMR screening, CADD, AIDD, protein production, and structural biology services.

Is CrystalsFirst a public or private company?

CrystalsFirst is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CrystalsFirst founded?

CrystalsFirst was founded in 2018. It employs 11 to 50 people.

Where is CrystalsFirst based?

CrystalsFirst is headquartered in Hamburg, Germany, in the Europe region.

How does CrystalsFirst make money?

One revenue line is on record: drug Discovery Services (CRO).

Who are CrystalsFirst's main competitors?

Direct peers on record are Evotec, Schrödinger, Vernalis (R&D Services) and XChem. Charles River Laboratories is listed as a broad incumbent. Emerging players are Isomorphic Labs, Recursion Pharmaceuticals, PostEra and Insitro. BioSolveIT is listed as an others.

Does CrystalsFirst have an API?

No public API is recorded for CrystalsFirst.

What industry is CrystalsFirst in?

CrystalsFirst's product category is Drug Discovery CRO Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals